John Lacey

Lead, R&D Corporate and Science Communications at Takeda, USA Swim Coach, Passionate Open Water Swimmer (opinions my own)

[John Lacey @JS_Lacey]

I'm excited to be speaking at Fierce Pharma PR and Communications Summit in Newport Beach, CA on May 14-15, 2024. To join me, click here: https://t.co/KdGh2mbpMI #FiercePharmaPR

[John Lacey @JS_Lacey]

Lots of great AI panels at #fierce@jpm2024 conference. Get a cool AI image of yourself at https://t.co/4fGzZy8eUI
#jpm2024 @FierceBiotech

[BioLineRx Limited @BioLineRx_Ltd]

For everyone at #JPM2024, we're excited to share this fun #ai photo experience with you. Try it out in person at our #FierceJPMWeek Table or online! https://t.co/D9oKr15rf9

Share your favorite results and tag #JPM2024, #FierceJPMWeek and BioLineRx.

[BioLineRx Limited @BioLineRx_Ltd]

JOIN US LIVE! BioLineRx US President, Holly May will be speaking tomorrow morning at the Hyatt Regency in SF. Register here: https://t.co/S8HNPl0N6a

#JPM2024 #FierceJPMWeek

[BioLineRx Limited @BioLineRx_Ltd]

BioLineRx ($BLRX) is looking forward to connecting with everyone at the 65th ASH Annual conference! If you're live for the event, stop by our Booth #3155 to meet the team! #ASH2023

[BioLineRx Limited @BioLineRx_Ltd]

We’re proud to announce FDA Approval of an innovative treatment to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. Join our management conference call Sept 12, 2023 at 8am EDT: https://t.co/aHhyEJ6b6G

[John Lacey @JS_Lacey]

So excited to share our new corporate platform and our mission to build a legacy of changing lives around the world.

[BioLineRx Limited @BioLineRx_Ltd]

Allow us to re-introduce BioLineRx! On the 20th anniversary of the company, we are excited to reaffirm and expand upon our purpose, which is to pursue life-changing therapies for certain cancers and rare diseases and work to ensure access to patients in need. (1/2)

[BioLineRx Limited @BioLineRx_Ltd]

BioLineRx today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. https://t.co/qJFEz96ZAO

[BioLineRx Limited @BioLineRx_Ltd]

BioLineRx ($BLRX) Announces Publication in @NatureMedicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma! https://t.co/JFSRY1dIHk

[Cision/PR Newswire Israel @PRNewswireIL]

#BioLineRx Announces #Publication in #Nature #Medicine of its #GENESIS #Phase 3 #Clinical #Trial #Data #Evaluating #Motixafortide and #G-CSF in #Stem #Cell #Mobilization for #Autologous #Transplantation in #Multiple #Myeloma https://t.co/wqOtkLWtTp @BioLineRx_Ltd $BLRX

[BioLineRx Limited @BioLineRx_Ltd]

The BioLineRx ($BLRX) Management and Medical Affairs Teams will be attending the TANDEM Meetings in person in Orlando, FL from February 15th-19th and are available for in-person discussions. Request a meeting! https://t.co/EokU1dzRFW #Tandem23

[BioLineRx Limited @BioLineRx_Ltd]

Wishing you the happiest of holidays from all of us at BioLineRx! We hope your celebrations are filled with joy and cheer!

[BioLineRx Limited @BioLineRx_Ltd]

For #MarrowAwarenessMonth we thank all transplant physicians, apheresis nurses & donors for their life-saving efforts. To learn more, check out these key myths & facts about bone marrow donation from @BeTheMatch: https://t.co/8ZGInUhLJ5

[BioLineRx Limited @BioLineRx_Ltd]

Join our team at the @ASH_hematology Annual Meeting, where we'll be presenting on the Cost-Effectiveness of Motixafortide in Multiple Myeloma and a Potential New Motixafortide Development Area in Gene Therapy! Read the full press release: https://t.co/l05obmaRqo #ASH22

[BioLineRx Limited @BioLineRx_Ltd]

Today we are excited to announce our plan to commercialize Motixafortide, now known by its FDA approved trade name APHEXDA, independently in the U.S., assuming FDA approval next year. To learn more, register for our upcoming webinar https://t.co/7elXzUpjlX $BLRX

[Mike Huckman @MikeHuckman]

Privileged to moderate this panel late today with Bob, Klavs and Armon, co-founders of this client company.

[SQZBiotech @SQZBiotech]

Today at #ASGCT22 we share preclinical data that shows that our SQZ® Point-of-Care manufacturing system could produce our Activating Antigen Carrier (AAC) therapeutic candidate in under 6 hours: https://t.co/hiyfGBc86X #celltherapy

[SQZBiotech @SQZBiotech]

Two major limitations of current cell therapy processes are access to biology and high cost of manufacturing. With the POC implementation of Cell Squeeze® technology, we feel we offer the ability to drive cell therapies into broad patient use across disease areas-@ArmonSharei

[SQZBiotech @SQZBiotech]

Ultimately, our vision is to produce and release SQZ® cell therapies at the hospital, to potentially enable same day treatment for patients – Howard Bernstein, MD, PhD

[SQZBiotech @SQZBiotech]

Key strengths of Cell Squeeze® manufacturing are flexibility and scalability, which allow us to be able to rapidly test new concepts. Our eAPC trial is a prime example of this as it went from concept to IND relatively quickly. - @ArmonSharei